---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010786"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:02:29.209816+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics pays ~$225M upfront to cancel Censa sepiapterin royalty obligations

## Summary
- Upfront cash payment of ~$225M to former Censa securityholders eliminates 8-12% annual net sales royalties.
- Original milestones: 8% on sales ≤$250M, 10% on $250M-$500M, 12% on >$500M.
- Additional Milestone Payments up to $100M each (total $500M) based on cumulative net sales thresholds (e.g., $3B, $5B, $7B, $9B, $11B).
- Participation was ~90% of former Censa securityholders; remaining may join and receive pro rata consideration.
- Sepiapterin is the product; other merger obligations remain unchanged.

## SEC filing metadata
- accession: 0001558370-25-010786
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/0001558370-25-010786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/tmb-20250805x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010786
- JSON: https://secwatch.observer/filing/0001558370-25-010786.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.